Management anticipates "initiation of a Phase I/IIa trial [for ABS-201] in early '26 with potential interim efficacy and proof-of-concept data anticipated later that year." Jonasson expects to "sign ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results